Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?

31 Jan 2014

• By Wendy Diller

Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.

FDA’s approval of a three-times weekly formulation of Copaxone was an important victory for beleaguered Teva Pharmaceutical Industries Ltd. But Teva’s success in defending its most important franchise depends on a lot more than offering just a more convenient alternative to its existing multiple sclerosis blockbuster.

The good news for Teva is that the new formulation, approved Jan. 28, is the same compound and has the...